These data, along with the findings at 30 weeks, suggest that hepatocyte-specific SAMHD1 deficiency alleviates liver steatosis, reduces lipid and cholesterol accumulation, and mitigates liver injury in the GAN diet-induced MASLD mouse model. Here, SAMHD1 is linked to metabolic dysfunction-associated steatotic liver disease.